TY - JOUR
T1 - Novel approaches to the management of myeloma
AU - Rajkumar, S. Vincent
PY - 2005
Y1 - 2005
N2 - Standard therapy for multiple myeloma, which accounts for 10% of all hematologic malignancies, has been autologous stem cell transplantation (ASCT), alkylator-based chemotherapy, and corticosteroids. Several advances have been made in the treatment of multiple myeloma over the past decade, especially the arrival of new, active agents such as thalidomide (Thalomid), bortezomib (Velcade), and lenalidomide (Revlimid). These have shown significant clinical activity as single agents. Trials are ongoing to incorporate these new agents into the various stages of treatment and to combine them with other effective treatment modalities, including ASCT.
AB - Standard therapy for multiple myeloma, which accounts for 10% of all hematologic malignancies, has been autologous stem cell transplantation (ASCT), alkylator-based chemotherapy, and corticosteroids. Several advances have been made in the treatment of multiple myeloma over the past decade, especially the arrival of new, active agents such as thalidomide (Thalomid), bortezomib (Velcade), and lenalidomide (Revlimid). These have shown significant clinical activity as single agents. Trials are ongoing to incorporate these new agents into the various stages of treatment and to combine them with other effective treatment modalities, including ASCT.
UR - http://www.scopus.com/inward/record.url?scp=22144433731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22144433731&partnerID=8YFLogxK
M3 - Review article
C2 - 15948290
AN - SCOPUS:22144433731
SN - 0890-9091
VL - 19
SP - 621
EP - 625
JO - Oncology
JF - Oncology
IS - 5
ER -